SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis.
SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis.
复制标题
DOI：
10.1586/14737159.2.6.549
复制
发表时间：
2002-11-01
影响因子：
5.1
通讯作者：
Wright, George L Jr
中科院分区：
文献类型：
--
作者：
Wright, George L Jr
识别和理解细胞所有蛋白质的结构、相互作用和功能是后基因组时代的主要目标之一。基因组计划产生了大量的信息，极大地阐明了癌症的遗传基础。然而，它的福尔斯不足之处在于不能准确预测癌细胞或体液蛋白质组中蛋白质水平上发生的情况。希望通过破译癌症蛋白质组的改变，将发现生物标志物和生物标志物的模式，这将导致早期检测，诊断和治疗监测的改进。为了实现这一目标，将需要快速高通量蛋白质组学技术。SELDI蛋白质芯片生物标志物质谱系统似乎在这方面具有潜力，无论是生物标志物的发现，并作为一个潜在的临床诊断分析平台。
Identification and understanding the structures, interactions and functions of all of a cell's proteins is one of the major goals of the postgenome era. The genome project has produced a wealth of information that is greatly expounding the genetic basis of cancer. However, it falls short in not allowing for accurate prediction of what is happening at the protein level in a cancer cell or a body fluid proteome. It is the hope that, by deciphering the alterations in the cancer proteome, biomarkers and patterns of biomarkers will be found that will lead to improvements in early detection, diagnosis and treatment monitoring. To achieve this goal, rapid high-throughput proteomic technologies will be required. The SELDI ProteinChip Biomarker mass spectrometry system appears to have potential in this effort, both for biomarker discovery and as a potential clinical diagnostic assay platform.